

# eNOS (Phospho-Ser615) Antibody

Catalog No: #12137



Package Size: #12137-1 50ul #12137-2 100ul

Orders: [order@signalwayantibody.com](mailto:order@signalwayantibody.com)

Support: [tech@signalwayantibody.com](mailto:tech@signalwayantibody.com)


## Description

|                       |  |
|-----------------------|--|
| Product Name          | eNOS (Phospho-Ser615) Antibody   |
| Host Species          | Rabbit   |
| Clonality             | Polyclonal   |
| Purification          | Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide. |
| Applications          | WB   |
| Species Reactivity    | Hu Ms Rt   |
| Specificity           | The antibody detects endogenous levels of eNOS only when phosphorylated at serine 615.   |
| Immunogen Type        | peptide  |
| Immunogen Description | Peptide sequence around phosphorylation site of serine 615 (F-N-S(p)-I-S) derived from Human eNOS.   |
| Target Name           | eNOS   |
| Modification          | Phospho-Ser615   |
| Other Names           | Constitutive NOS; EC 1.14.13.39; EC-NOS; ECNOS; Endothelial NOS; NOS; type III; NOS3; NOSIII; Nitric-oxide synthase; endothelial; cNOS   |
| Accession No.         | Swiss-Prot#:P29474;NCBI Gene#:4846   |
| SDS-PAGE MW           | 140kd  |
| Concentration         | 1.0mg/ml   |
| Formulation           | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.  |
| Storage               | Store at -20°C   |

## Application Details

Western blotting: 1:500~1:3000

## Images



Western blot analysis of extracts from K562 cells, treated with EGF (40nM, 30mins), using eNOS (Phospho-Ser615) antibody #12137. The lane on the right is treated with the synthesized peptide.

## Background

---

Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.

Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.

---

Note: This product is for in vitro research use only and is not intended for use in humans or animals.